SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
1-Year Return
71.55%
This Quarter Return
+18.55%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$444M
AUM Growth
+$38.7M
(+9.5%)
Cap. Flow
+$6.85M
Cap. Flow
% of AUM
1.54%
Top 10 Holdings %
Top 10 Hldgs %
47.12%
Holding
80
New
13
Increased
27
Reduced
18
Closed
11
Top Buys
| 1 |
Insmed
INSM
|
$15.2M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$11.9M |
| 3 |
Vaxcyte
PCVX
|
$6.63M |
| 4 |
Protagonist Therapeutics
PTGX
|
$6.6M |
| 5 |
Veracyte
VCYT
|
$6.41M |
Top Sells
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$16.6M |
| 2 |
Nuvalent
NUVL
|
$9.64M |
| 3 |
Celldex Therapeutics
CLDX
|
$7.81M |
| 4 |
Corbus Pharmaceuticals
CRBP
|
$7.81M |
| 5 |
Mirum Pharmaceuticals
MIRM
|
$2.71M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Trevi Therapeutics
TRVI
$880M
| $1.61M | 0.36% |
482,575
-361,660
| -43% | -$1.21M |
|
52
Xencor
XNCR
$597M
| $1.52M | 0.34% |
+75,507
| New | +$1.52M |
|
53
Tarsus Pharmaceuticals
TARS
$2.42B
| $1.32M | 0.3% |
40,000
| – | – |
|
54
Kodiak Sciences
KOD
$452M
| $1.31M | 0.29% |
500,000
-562,062
| -53% | -$1.47M |
|
55
Evogene
EVGN
$10.5M
| $945K | 0.21% |
307,974
| – | – |
|
|
MTEM
56
DELISTED
Molecular Templates, Inc.
MTEM
| $876K | 0.2% |
623,838
| – | – |
|
57
Applied Therapeutics
APLT
$67M
| $850K | 0.19% |
+100,000
| New | +$850K |
|
|
VXRT
58
DELISTED
Vaxart
VXRT
| $849K | 0.19% |
+1,000,000
| New | +$849K |
|
59
EyePoint Pharmaceuticals
EYPT
$819M
| $799K | 0.18% |
100,000
| – | – |
|
60
Ascendis Pharma
ASND
$12B
| $747K | 0.17% |
+5,000
| New | +$747K |
|
61
Instil Bio
TIL
$205M
| $708K | 0.16% |
+10,517
| New | +$708K |
|
62
89bio
ETNB
$1.28B
| $683K | 0.15% |
92,298
| – | – |
|
63
Karyopharm Therapeutics
KPTI
$58.4M
| $464K | 0.1% |
37,231
| – | – |
|
64
Black Diamond Therapeutics
BDTX
$163M
| $435K | 0.1% |
+100,000
| New | +$435K |
|
65
Fractyl Health
GUTS
$63.8M
| $422K | 0.09% |
166,666
| – | – |
|
66
Aligos Therapeutics
ALGS
$74.7M
| $227K | 0.05% |
26,219
-2
| -0% | -$17 |
|
67
VYNE Therapeutics
VYNE
$7.91M
| $144K | 0.03% |
76,784
-390,613
| -84% | -$734K |
|
68
Rocket Pharmaceuticals, Inc. Warrant
RCKTW
$4.17M
| $6.76K | ﹤0.01% |
104,828
| – | – |
|
69
ALX Oncology
ALXO
$57.8M
| – | – |
0
| – | – |
|
|
70
Corbus Pharmaceuticals
CRBP
$123M
| – | – |
-172,492
| Closed | -$7.81M |
|
71
enGene Holdings
ENGN
$256M
| – | – |
-263,841
| Closed | -$2.49M |
|
72
Fulcrum Therapeutics
FULC
$372M
| – | – |
-398,436
| Closed | -$2.47M |
|
73
Jasper Therapeutics
JSPR
$43.7M
| – | – |
-109,892
| Closed | -$2.49M |
|
74
MacroGenics
MGNX
$123M
| – | – |
-370,000
| Closed | -$1.57M |
|
|
75
Mirum Pharmaceuticals
MIRM
$3.73B
| – | – |
-79,194
| Closed | -$2.71M |
|